Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - A real-world outcomes analysis Journal Article
| Authors: | Abedin, S.; Rashid, N.; Schroeder, M.; Romee, R.; Nauffal, M.; Alhaj Moustafa, M.; Kharfan-Dabaja, M. A.; Palmer, J.; Hogan, W.; Hefazi, M.; Larson, S.; Holtan, S.; DeFilipp, Z.; Jayani, R.; Dholaria, B.; Pidala, J.; Khimani, F.; Grunwald, M. R.; Butler, C.; Hamadani, M. |
| Article Title: | Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - A real-world outcomes analysis |
| Abstract: | Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies. © 2021 British Society for Haematology and John Wiley & Sons Ltd |
| Keywords: | adult; controlled study; treatment outcome; aged; middle aged; survival rate; treatment failure; major clinical study; neutropenia; drug safety; drug withdrawal; united states; treatment indication; anemia; gastrointestinal symptom; thrombocytopenia; stem cell transplantation; retrospective study; patient identification; drug hypersensitivity; cause of death; patient participation; acute graft versus host disease; laboratory test; multicenter study; etanercept; pancytopenia; hyperbilirubinemia; drug use; multiple organ failure; transplant; posttransplant lymphoproliferative disease; graft-versus-host disease; overall response rate; photopheresis; tocilizumab; cardiogenic shock; ruxolitinib; human; article; population structure |
| Journal Title: | British Journal of Haematology |
| Volume: | 195 |
| Issue: | 3 |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2021-11-01 |
| Start Page: | 429 |
| End Page: | 432 |
| Language: | English |
| DOI: | 10.1111/bjh.17700 |
| PUBMED: | 34254289 |
| PROVIDER: | scopus |
| PMCID: | PMC9293486 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 December 2021 -- Source: Scopus |
